This is an increase from the 55 treatments and 38 vaccine candidates identified when the Institute first started tracking treatments and vaccines in early March.
Of these, nine vaccines and more than 50 treatments currently are in clinical trials. These include the RECOVERY study, the World Health Organization's Solidarity Study, the National Institute of Allergy and Infectious Diseases' Adaptive COVID-19 Treatment Trial, and the REMAP-CAP trial.
A new, interactive version of the tracker makes the data searchable and sortable. Graphics capture the progress made, and the raw data can also be downloaded offline in a useable spreadsheet format. The tracker is updated regularly.
The COVID-19 Treatment and Vaccine Tracker is produced and maintained by FasterCures, with input from its Advisory Council, which includes three former FDA chiefs, a Nobel Laureate biologist, and key industry leaders.
The information is compiled by publicly-available information from validated sources.
The Milken Institute is a nonprofit, nonpartisan think tank.
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy
Eli Lilly and Co receives approval from FDA for Zepbound
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment
Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)
Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial
CBC Group acquires UCB's mature neurology and allergy business in China